Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | ATP4A | P20648 | 9/20 | 0.44 |
| ▸ | ATP4B | P51164 | 9/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675815 | 1.00 | ALK (0.48) | ALKBCHEACHEATP4AATP4B | |
| SCHEMBL3725532 | 0.86 | ESR1 (0.39) | ACHEATP4AATP4BMCHR1MAOA | |
| SCHEMBL3725535 | 0.86 | ESR1 (0.39) | ACHEATP4AATP4BMCHR1MAOA | |
| SCHEMBL13460975 | 0.86 | ALK (0.48) | ALK | |
| SCHEMBL675132 | 0.84 | ACHE (0.47) | ACHEATP4AATP4B | |
| SCHEMBL676194 | 0.83 | ALK (0.67) | ALKBCHE | |
| SCHEMBL678727 | 0.83 | ALK (0.67) | ALKBCHE | |
| SCHEMBL675816 | 0.83 | HRH3 (0.42) | BCHEACHEATP4AATP4B | |
| SCHEMBL3433144 | 0.80 | HRH3 (0.40) | ACHEATP4AATP4BMCHR1 | |
| SCHEMBL3725897 | 0.78 | LSS (0.39) | ALKATP4AATP4BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | ALK 1/4885BCHE 2019/4885ACHE 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.